Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.
Pennings ER, Spanjaart AM, Thielen FW, Oerlemans S, Fleischer A, Sanges C, Gomes Da Silva M, Cabrerizo Y, Lecot P, Roux-Opstaele L, Dreuillet C, Gonzalez-Marcano E, Millán O, Jaeger U, Delgado J, Luu M, Huber B, Lorrain M, Galhardas Pina M, Kremer A, Bolanos N, Clavreul S, Nier S, Liu RDK, Lissenberg-Witte BI, Anguille S, Robin M, Morris EC, Sureda A, Préau M, Pannard M, De Bock GH, Wagers SS, Trebeden-Negre H, Maucort-Boulch D, Hudecek M, Uyl-de Groot CA, Kersten MJ.
Pennings ER, et al. Among authors: wagers ss.
Blood Adv. 2025 Sep 24:bloodadvances.2025017081. doi: 10.1182/bloodadvances.2025017081. Online ahead of print.
Blood Adv. 2025.
PMID: 40991391